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AbstrAct
Background The right ventricle (RV) is not designed 
to sustain high pressure leading to failure. There are 
no current medications to help RV contraction, so 
further information is required on adaption of the RV 
to such hypertension.
Methods The Right Ventricle in Children (RVENCH) 
study assessed infants with congenital heart disease 
undergoing cardiac surgery with hypertensive RV. 
Clinical and echocardiographic data were recorded, 
and samples of RV were taken from matched infants, 
analysed for proteomics and compared between 
pathologies and with clinical and echocardiographic 
outcome data.
Results Those with tetralogy of Fallot (TOF) 
were significantly more cyanosed than those with 
ventricular septal defect (median oxygen saturation 
83% vs 98%, P=0.0038), had significantly stiffer 
RV (tricuspid E wave/A wave ratio 1.95 vs 0.84, 
P=0.009) and had most had restrictive physiology. 
Gene ontology in TOF, with enrichment analysis, 
demonstrated significant increase in proteins of 
contractile mechanisms and those of calmodulin, 
actin binding and others associated with contractility 
than inventricular septal defect. Structural proteins 
were also found to be higher in association with 
sarcomeric function: Z-disc, M-Band and thin-filament 
proteins. Remaining proteins associated with actin 
binding, calcium signalling and myocyte cytoskeletal 
development. Phosphopeptide enrichment led to 
higher levels of calcium signalling proteins in TOF.
Conclusion This is the first demonstration that 
those with an RV, which is stiff and hypertensive 
in TOF, have a range of altered proteins, often in 
calcium signalling pathways. Information about these 
alterations might guide treatment options both in 
terms of individualised therapy or inotropic support 
for the Right ventricle when hypertensive due to 
pulmoanry hypertension or congenital heart disease. 
BaCkgRound
It is estimated that about 1% of all live-born 
babies are affected by cardiac congenital 
malformations. Intracardiac surgical repair in 
these patients is associated with a low mortality 
in infants and children (<5%). More impor-
tantly, a growing number of patients survive 
into adulthood with hypertensive right ventri-
cles (RV). Heart failure due to RV dysfunction 
is a major cause of morbidity in this popula-
tion, and a significant proportion of them will 
die as a result. There is recent evidence that the 
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Basic and translational research
Key questions
What is already known about this subject?
 ► Proteomic changes in myocardium have been 
studied in adult patients with or without ischaemic 
arrest, and our laboratory has identified genetic 
changes in the myocardium of children undergoing 
cardiac surgery.
What does this study add?
 ► To date, this is a unique study that identifies 
the proteomic differences in right ventricular 
myocardium from infants undergoing cardiac 
surgery for cyanotic and acyanotic heart diseases 
with a hypertensive right ventricle.
How might this impact on clinical practice?
 ► It is of clinical concern how to manage such 
children, as to the timing of surgery, the type of 
inotrope that might benefit the child with each 
cardiac condition and individual mechanisms 
that might be accessed in precision medicine to 
determine the best therapy for each child. This 
study is the first step in that process to identify the 
mechanisms involved and the best treatment for 
the individual child.
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mortality is increasing in the teenage population who are 
dying of the complications of cardiac surgery performed 
over a decade ago, and it is our responsibility to improve 
this for the next generation.1 The gravity of the problem 
is well explained by the 2009 WHO annual report that 
puts the disability-adjusted life-year for congenital heart 
disease higher than diseases such as diabetes or hyperten-
sion.2 At present, pharmacotherapy of heart failure may 
improve clinical symptoms, but there is no targeted phar-
macotherapy to improve RV systolic and diastolic function 
or to prevent or even reverse the remodelling of the RV. 
Significant morbidity secondary to RV dysfunction leads to 
greater length of time on the paediatric intensive care unit 
(PICU) postoperatively and more expensive repeat inter-
ventions and reoperations. Since each day on the PICU 
can cost up to £2000, and each reoperation costs £25000, 
it will be beneficial to the healthcare economy to improve 
the quality of individualised care we deliver to these chil-
dren.
One drawback in this area is the fact that patients with RV 
dysfunction are grouped together despite the fact that there 
are different congenital cardiac disorders that will trigger 
different functional, molecular and cellular remodelling in 
the RV. It is therefore vital to dissect potential differences 
in cell signalling and remodelling in patients with different 
causes of RV dysfunction. Consequently, a greater under-
standing of the underlying mechanisms of RV function in 
different congenital cardiac disorder groups will help to 
formulate strategies targeting individual cardiac disorders. 
The National Heart, Lung, and Blood Institute (Bethesda, 
Maryland, USA) has been awarded top priority to research 
on pathophysiology of the RV. RV dysfunction is caused 
by changes in the cell fate and tissue composition. These 
changes occur due to cell signalling that may be initiated by 
various factors including oxidative stress and lead to alter-
ations in cell survival, structural (cytoskeletal) and extra-
cellular proteins, protease activity and calcium handling 
properties.3 From our recent studies, we have shown that 
chronic hypoxaemia in cyanotic children with tetralogy of 
Fallot (TOF) induced the expression of genes associated 
with apoptosis and reduced the expression of genes associ-
ated with normal myocyte contractility and function.3
It is well established that convergence of the signalling 
pathways activated by tumour growth factor-β, Wnts and 
cadherin are critical for development and its importance 
re-emerge in disease. It plays a key role in cell fate (growth 
and survival) and in matrix synthesis and remodelling, 
which are all pertinent processes in RV dysfunction. We 
already have extensive evidence for their important role 
in blood vessel remodelling and propose that modulation 
of these signalling pathways contribute to RV dysfunction. 
Although right ventricular failure (RVF) is the hallmark of 
pulmonary arterial hypertension (PAH), the mechanism 
of RVF is unclear. Development of PAH-induced RVF is 
associated with an increased reactive oxygen species (ROS) 
production. Increases in oxidative stress lead to generation 
of nitro-tyrosine residues in tissue inhibitor of metallopro-
teinase and liberate active matrix metalloproteinase.4
The purpose of this study is to investigate the cellular 
signalling changes associated with RV hypertension in the 
setting of congenital heart disease. This would lead to a 
better understanding of the determinants of RV function in 
patients with hypertrophy associated with different congen-
ital cardiac malformations. It was proposed that:
1. Changes in key myocardial cellular signalling pathways 
triggered by hypertension-induced RV dysfunction in 
congenital cardiac disorders depend on the type of 
malformation and systemic oxygen saturation.
2. The pathology-induced cellular and molecular chang-
es will result in differences in postoperative stay within 
the hospital.
3. Identifying differences in the cellular signalling 
pathways between those with large septal defects and 
those with TOF might enable us to tailor therapies for 
each pathology to improve outcome.
The clinical outcome in our patients often depends on 
the ability of the RV to cope with the anatomical substrate 
and the effect of cardiopulmonary bypass. We hoped to 
be able to understand better the effect of these and hence 
to modify our treatment accordingly. This might lead to 
better and perhaps individualised care for our patients 
undergoing cardiopulmonary bypass for congenital heart 
diseases.
Patients and methods
Inclusion criteria
We compared patients with RV hypertension who under-
went cardiopulmonary bypass and consented for inclu-
sion between 1 July 2015 and 31 March 2017. We report 
on two groups of children with right ventricular pressures 
at systemic level: group 1: pulmonary hypertension due to 
large septal defects, such as ventricular septal defect (VSD) 
and group 2: obstructed RV (as in TOF). In group 1, left 
to right shunt was the cause of RV hypertension. In group 
2, the children were cyanosed, and the RV was functioning 
under a significant obstructive afterload.
Exclusion criteria
Children with additional syndromes were excluded (apart 
from Trisomy 21) due to the unknown effect on ventricular 
function and protein analysis. Parents who were not able 
to consider the information at least 1 week before opera-
tion were excluded, hence excluding any children under-
going emergency surgery. In addition, we excluded those 
with sepsis or coexisting morbidity, which might alter the 
protein analysis.
Fully informed consent was obtained from parents prior 
to admission for operation. Clinical data were obtained from 
patient’s clinical records and Heartsuite Database at the 
time of cardiac surgery. Demographic data were recorded, 
including details of cardiac anatomy and systemic oxygen 
saturations. At operation, tissue samples were obtained 
from right ventricular myocardium as soon as possible after 
instituting cardiopulmonary bypass to minimise the effect 
of this on protein analysis.
Protein analysis technique is online supplement.
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Table 1 Patient demographics, preoperative and 
intraoperative characteristics
Group 1 
VSD
Group 2 
TOF P value
Age (years) 0.38 (0.13) 0.37 (0.13) ns
Weight (kg) 4.81 (0.41) 5.89 (1.01) ns
Oxygen saturations (%) 97.5 (2.6) 82.8 (6.2) 0.0038
Male:female 3:3 3:3 ns
Systolic blood pressure 
(mm Hg)
83.8 (10.9) 88.5 (13.6) ns
Fractional shortening (%) 34.7 (2.5) 34.0 (8.5) ns
Bypass time (minutes) 117 (127) 140 (28) ns
Cross-clamp time (minutes) 86 (95) 87(51) ns
Data displayed as mean (SD).
P<0.05 was significant.
TOF, tetralogy of Fallot; VSD, ventricular septal defect.
Table 2 Echocardiographic assessment postoperatively, 
comparison of VSD group and TOF group
Group 1 
VSD
Group 2 
TOF P value
Heart rate 125 (14) 141 (14) 0.044
Fractional shortening (%) 30.43 (2) 32.5 (4) ns
MAPSE (mm) 7 (1) 6.8 (1) ns
Aortic VTI (mL/s) 12.2 (3) 13 (3) ns
TAPSE (mm) 6 (1) 7.43 (2) ns
Tricuspid E/A ratio 0.84 (0.3) 1.95 (0.4) 0.009
Tricuspid S′ (cm/s) 6 (1) 4.7 (1) ns
Pulmonary A wave 0/6  5/6 0.001
Data displayed as mean (SD).
P<0.05 is significant.
E/A ratio, E wave/A wave ratio; MAPSE, mitral annular plane 
systolic excursion; S′, tissue Doppler assessment of free wall 
movement; TAPSE, tricuspid annular plane systolic excursion; TOF, 
tetralogy of Fallot; VSD, ventricular septal defect; VTI, velocity time 
integral.
Basic and translational research
Clinical data
The patient clinical outcome data that was recorded were 
standard operative and postoperative data. This included 
bypass time, cross clamp time, recorded pressure in the 
superior vena cava at 4 hours postoperative, time in inten-
sive care, time on mechanical ventilation, time of pleural 
effusion drainage, requirement for postoperative oxygen 
therapy and time to discharge. In addition, we recorded 
the requirement for inotropic support both for length of 
time this was needed but also which inotrope was used.
Tissue studies
Biopsies were taken from the free wall of the RV of patients 
with VSD (n=6) or with TOF (n=6) immediately after 
starting cardiopulmonary bypass. Tissue was either snap 
frozen in liquid nitrogen or placed in Allprotect tissue 
reagent (Qiagen, Manchester, UK) before being stored at 
−80°C.
Echocardiography
Echocardiography was performed using a Vivid 9 or IE33 
echocardiographic machines using standard assessment of 
preoperative and postoperative characteristics, including 
cardiac anatomy in addition to function. Left heart func-
tion assessment included fractional shortening in long axis 
view, mitral annular plane systolic excursion (not indexed), 
mitral E wave/A wave (E/A wave) ratio and volume time 
integral of left ventricular outflow tract Doppler. Right 
heart function similarly included tricuspid annular plane 
systolic excursion (not indexed), fractional area length 
change and lateral wall tissue Doppler. An assessment was 
made of diastolic function by Doppler interrogation of 
inflow velocity through the mitral and tricuspid valve and 
also the presence or absence of diastolic A wave velocity in 
the pulmonary artery.
Statistical comparison
For the data that were parametric, mean and SD are 
presented with paired t-test values (P<0.05 being signif-
icant). For the data that were non-parametric, median 
(range) is presented with Wilcoxon values (P<0.05 being 
significant). Significance of proteomic data was deter-
mined as described above.
RESulTS
Clinical data
The demographic and clinical data are displayed in 
table 1; children in each group had similar age, sex ratio 
and weight. On preoperative echocardiogram, all chil-
dren had systemic level right ventricular pressure, with 
an unrestrictive VSD. Those with TOF were significantly 
cyanosed, with severe infundibular pulmonary stenosis. 
All had good systolic function preoperatively, and there 
was no difference in bypass time or cross-clamp time at 
operation.
Postoperatively, there were some differences in the RV 
function, as seen in table 2. Those from the TOF group 
having good systolic function and good cardiac output. 
However, there was evidence of increased stiffness in the 
RV with a significantly higher tricuspid E/A ratio (VSD 
group 0.84 (0.3) compared with TOF group 1.95 (0.4) 
(P=0.009) and high incidence of pulmonary diastolic 
forward flow (A wave) (0/6 in the VSD group and 5/6 in 
the TOF group (P=0.001)).
Proteomics analysis
A total of 3610 protein accession numbers (representing 
3342 gene names; note that this number differs in 
table 3 (2357 gene names) due to the PantherDB data-
base version used) were identified that were found in 
RV samples from both heart pathologies and that fulfilled 
all criteria outlined above. Of these, 200 were found to 
significantly change (±1.3-fold, P<0.05) between patholo-
gies: 26 were lower in TOF samples and 174 were higher 
in TOF (figure 1). Gene ontology analysis was performed 
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Figure 1 Volcano plot of entire set of proteins quantified in the right ventricle of TOF versus VSD patients (positive log2 (fold 
change) indicates higher expression in TOF samples). Each point represents the difference in expression (log2 fold difference) 
between the groups, and the associated significance of this change (independent unpaired samples t-test). Proteins 
significantly altered (±1.3-fold, P<0.05) are found within the grey shaded boxes. TOF, tetralogy of Fallot; VSD, ventricular septal 
defect.
using these proteins found in both TOF and VSD samples 
and which significantly changed or not (table 4).
Four hundred and fourteen phosphorylated proteins 
were also successfully identified, each containing at least 
one translation modification at serine, threonine or 
tyrosine (resulting in a total of 700 phosphorylation site 
matches). Of the phosphorylation sites identified, 117 
significantly changed representing 97 unique proteins: 
46 were lower in TOF and 71 were higher (figure 2).
Gene ontology enrichment analysis showed that 
cellular component proteins associated with the muscle/
contractile fibre part (11 proteins) and specifically the 
Z-disc (eight proteins) were significantly enriched in 
those proteins that were higher in patients with TOF. For 
individual proteins associated with Gene Ontology (GO) 
terms, see table 5. Proteins and associated gene names 
are displayed in table 6. Molecular function proteins 
associated with α-catenin, calmodulin and cytoskeletal 
actin binding (3, 7 and 14 proteins, respectively) were 
enriched, as well as biological processes predominantly 
associated with heart and muscle contractility and regu-
lation (figure 3). There was no enrichment of proteins 
higher in VSD patients. Phosphorylated proteins associ-
ated with the biological processes actomyosin structure 
organisation, regulation of calcium-mediated signalling 
and regulation of calcium ion transmembrane trans-
porter activity (5, 3 and 3 phosphoproteins, respectively), 
and the cellular components somatodendritic compart-
ment, Z-disc and actomyosin (2, 4 and 5 phosphopro-
teins, respectively) were significantly enriched.
Structural and extracellular matrix protein and calcium 
signalling comparisons
Structural proteins in human skeletal muscle were 
cross-referenced against protein lists found in our 
different samples. One hundred and nine accession 
numbers (representing 97 proteins) were detected, and 
12 (12.4%) of these were significantly higher in TOF. Six 
of these were associated with sarcomeric function that 
included Z-disc proteins (muscle LIM protein (CSRP3), 
filamin-C, ZASP), M-band and giant muscle proteins 
(myomesin-1 and obscurin) and the thin filament 
protein, tropomyosin-1. The remaining six proteins were 
associated with actin-binding (supervillin, cardiomyopa-
thy-associated protein 5, synaptopodin 2-like protein and 
cordon-bleu protein), calcium signalling (phospho-
lamban) and myocyte cytoskeletal development (striated 
muscle preferentially expressed protein kinase; by simi-
larity with members of myosin light chain kinase family). 
Additionally, adenylate cyclase six was higher in TOF 
samples. Phosphopeptide enrichment led to higher levels 
of 9 proteins in TOF samples compared with VSD, some 
with multiple phosphorylation sites. These were calcium 
signalling proteins (neuroblast differentiation-associ-
ated protein AHNAK–Ser4425 and AHNA K–Ser5110, 
sarcoplasmic reticulum histidine-rich calcium-binding 
protein –Ser145 and –Ser457, junctophilin-2 –Threo-
nine (Thr)490, phospholamban-Ser16 and phospholam-
ban-Ser16/Thr17), Z-disk proteins (obscurin-Ser5563 
and dystrophin-Ser432), BAG family molecular chap-
erone regulator 3-Ser289 (which stimulates expression 
of cytoskeleton), striated muscle preferentially expressed 
protein kinase-Ser2448 and protein kinase-Ser2014/
Ser2015, and nuclear ubiquitous casein and cyclin-de-
pendent kinase substrate-Ser113 (highly expressed in 
cardiac tissue, but with unknown function). Six phosphop-
roteins had lower levels in TOF samples: AHNAK-Ser1068 
and AHNAK-Ser5369 (calcium signalling), myomes-
in-1-Ser36 and myomesin-2-Ser39, myomesin-2-Ser76, 
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Figure 2 Volcano plot of entire set of phosphorylated proteins quantified in the right ventricle of TOF versus VSD patients 
(positive log 2 (fold change) indicates higher expression in TOF samples). Each point represents the difference in expression 
(log 2 fold difference) between the groups, and the associated significance of this change (independent unpaired samples 
t-test). Proteins significantly altered (±1.3 fold, P<0.05) are found within the grey shaded boxes. TOF,  tetralogy of Fallot; VSD, 
ventricular septal defect. 
Basic and translational research
myomesin-2-Ser78, myomesin-2-Ser1461 (M-band 
proteins), Xin actin-binding repeat-containing protein 
1-Ser208 (actin-binding) and protein kinase cAMP-de-
pendent regulatory type II alpha-Ser78 (protein kinase 
activity).
Of the list of extracellular matrix proteins searched, 
four were higher in VSD (collagen VI, keratin-10 and 
keratin-14 and tubulin-β4 A), and five were higher in TOF 
samples (cofilin-2, cadherin-2, myomesin-1, tropomy-
osin-1 and tubulin-α4 A). Additionally, three phosphor-
ylated proteins were lower in TOF samples: myomesin 
1-Ser36 (also in structural proteins list), myomesin 2 at 
phosphosites-Ser39, phosphosites-Ser76 and phospho-
sites-Ser1461 and troponin I at Ser199.
Clinical outcome data
All children survived without any major complications. 
However, as expected there were significant differ-
ences in outcome data (table 7). The number of days of 
mechanical ventilation, the pressure in the superior vena 
cava at 4 hours, the peak rate of dopamine, the length 
of time of required dopamine infusion, the peak rate 
of milrinone, the length of time of milrinone require-
ment and the number of days of pleural drains in situ 
were all not significantly different in the two groups. One 
child with TOF had longer time in intensive care, longer 
time on milrinone, longer hospital stay and longer time 
in oxygen than the others. As a result, there was a mildly 
significant difference in the length of time that supple-
mental oxygen was required between the VSD group and 
the TOF group. However, this all resolved by discharge. 
Two children had arrhythmias in the VSD group and 
one with supraventricular tachycardia and with complete 
heart block but both resolved by the time of leaving the 
intensive care. Three children with TOF had junctional 
ectopic tachycardia but resolved with standard approach 
of cooling and short-term amiodarone usage. None 
required long-term medication. All children were 
discharged home on furosemide and spironolactone. 
Two children with VSD repair were discharged home 
on captopril. One child with TOF required captopril at 
discharge and one child had propranolol for stiff RV.
diSCuSSion
The present study is the first to attempt to correlate 
changes in myocardial proteins with clinical and echo-
cardiographic data in order to try to understand the 
adaptive, maladaptive and remodelling pathways in the 
two groups of patients with hypertensive RVs. These two 
groups were chosen since they both have RVs that were 
functioning at systemic pressure. Both groups of infants 
were of the same age at the time of operation, and there 
was the same sex distribution. Hence, confounders 
relating to these diseases have been removed. The only 
difference between the two groups was the physiology—
one being volume loaded and the other being after 
loaded—in addition to the systemic oxygen saturation 
being significantly lower in the group with TOF.
We confirmed previous studies that have shown the 
RV to be stiff in those children who have TOF,5 and our 
gene ontology protein enrichment data lends further 
support to this, with proteins found to be higher in 
patients with TOF in the contractile part of the cell and 
in particular the Z-disc. Enrichment of differentially 
expressed proteins within processes regulating heart and 
muscle contractility also support this.
The contractile units of myocytes are the sarcomeres, 
and within these, the thin actin filaments and thick 
myosin filaments generate the contractile force. Many 
group.bmj.com on February 21, 2018 - Published by http://openheart.bmj.com/Downloaded from 
Open Heart
10 Bond AR, et al. Open Heart 2018;5:e000716. doi:10.1136/openhrt-2017-000716
Ta
b
le
 5
 
E
nr
ic
he
d
 g
en
e 
on
to
lo
gy
 t
er
m
s 
fo
r 
si
gn
ifi
ca
nt
ly
 h
ig
he
r 
to
ta
l a
nd
 p
ho
sp
ho
ry
la
te
d
 p
ro
te
in
 le
ve
ls
 in
 t
he
 r
ig
ht
 v
en
tr
ic
le
 o
f p
at
ie
nt
s 
w
ith
 t
et
ra
lo
gy
 o
f F
al
lo
t 
co
m
p
ar
ed
 
w
ith
 v
en
tr
ic
ul
ar
 s
ep
ta
l d
ef
ec
t
O
nt
o
lo
g
y
P
ro
te
in
 t
yp
e
G
O
 t
er
m
D
es
cr
ip
ti
o
n
P
 v
al
ue
 P
ro
te
in
s 
(n
)
P
ro
te
in
 s
ym
b
o
l
Ce
llu
la
r c
om
po
ne
nt
To
ta
l
GO
:0
04
44
49
Co
nt
ra
ct
ile
 fi
br
e 
pa
rt
4E
-0
5
11
CF
L2
, C
M
YA
5,
 C
SR
P3
, F
HO
D3
, F
LN
C,
 M
YO
M
1,
 M
YO
Z2
, N
EB
L,
 O
BS
CN
, R
YR
2,
 
SV
IL
GO
:0
03
00
18
Z-
di
sc
9E
-0
5
8
CF
L2
, C
SR
P3
, F
HO
D3
, F
LN
C,
 M
YO
Z2
, N
EB
L,
 O
BS
CN
, R
YR
2
Ph
os
ph
or
yl
at
ed
GO
:0
04
26
41
Ac
to
m
yo
si
n
6E
-0
5
4
CD
C4
2B
PB
, M
YO
18
A,
 N
EB
L,
 S
OR
BS
1
GO
:0
03
64
77
So
m
at
od
en
dr
iti
c 
co
m
pa
rtm
en
t
1E
-0
4
2
M
AP
T,
 S
TX
4
GO
:0
04
44
49
Co
nt
ra
ct
ile
 fi
br
e 
pa
rt
7E
-0
4
5
AH
NA
K,
 B
AG
3,
 J
PH
2,
 N
EB
L,
 O
BS
CN
GO
:0
03
00
18
Z-
di
sc
8E
-0
4
4
BA
G3
, J
PH
2,
 N
EB
L,
 O
BS
CN
M
ol
ec
ul
ar
 fu
nc
tio
n
To
ta
l
GO
:0
04
52
94
Al
ph
a-
ca
te
ni
n 
bi
nd
in
g
1E
-0
5
3
AJ
UB
A,
 C
DH
2,
 P
KP
2
GO
:0
00
37
79
Ac
tin
 b
in
di
ng
4E
-0
5
14
AJ
UB
A,
 C
FL
2,
 C
SR
P3
, F
HO
D3
, F
LI
I, 
FL
NC
, L
IM
CH
1,
 M
YO
Z2
, N
EB
L,
 S
NT
A1
, 
SN
TB
2,
 S
OR
BS
1,
 S
VI
L,
 T
W
F2
GO
:0
00
55
16
Ca
lm
od
ul
in
 b
in
di
ng
9E
-0
4
7
CA
M
K2
D,
 O
BS
CN
, P
PP
3C
C,
 R
YR
2,
 S
NT
A1
, S
NT
B2
, S
TR
N
Bi
ol
og
ic
al
 p
ro
ce
ss
GO
:0
01
08
81
Re
gu
la
tio
n 
of
 c
ar
di
ac
 m
us
cl
e 
co
nt
ra
ct
io
n 
by
 re
gu
la
tio
n 
of
 th
e 
re
le
as
e 
of
 s
eq
ue
st
er
ed
 c
al
ci
um
 io
n
3E
-0
5
4
CA
M
K2
D,
 G
ST
M
2,
 P
LN
, R
YR
2
GO
:0
03
10
32
Ac
to
m
yo
si
n 
st
ru
ct
ur
e 
or
ga
ni
sa
tio
n
9E
-0
5
7
CF
L2
, C
SR
P3
, F
HO
D3
, L
IM
CH
1,
 M
YO
Z2
, O
BS
CN
, S
OR
BS
1
GO
:0
01
08
82
Re
gu
la
tio
n 
of
 c
ar
di
ac
 m
us
cl
e 
co
nt
ra
ct
io
n 
by
 c
al
ci
um
 io
n 
si
gn
al
lin
g
9E
-0
5
4
CA
M
K2
D,
 G
ST
M
2,
 P
LN
, R
YR
2
GO
:0
01
47
06
St
ria
te
d 
m
us
cl
e 
tis
su
e 
de
ve
lo
pm
en
t
1E
-0
4
6
CF
L2
, C
SR
P3
, M
YO
M
1,
 P
LN
, S
EM
A3
C,
 S
VI
L,
GO
:1
90
35
22
Re
gu
la
tio
n 
of
 b
lo
od
 c
irc
ul
at
io
n
1E
-0
4
9
AD
CY
6,
 C
AM
K2
D,
 C
SR
P3
, G
ST
M
2,
 P
KP
2,
 P
LN
, R
YR
2,
 S
NT
A1
, T
M
EM
65
GO
:0
06
05
37
M
us
cl
e 
tis
su
e 
de
ve
lo
pm
en
t
1E
-0
4
6
CF
L2
, C
SR
P3
, M
YO
M
1,
 P
LN
, S
EM
A3
C,
 S
VI
L
GO
:0
01
08
80
Re
gu
la
tio
n 
of
 re
le
as
e 
of
 s
eq
ue
st
er
ed
 c
al
ci
um
 io
n 
in
to
 c
yt
os
ol
 b
y 
sa
rc
op
la
sm
ic
 re
tic
ul
um
2E
-0
4
4
CA
M
K2
D,
 G
ST
M
2,
 P
LN
, R
YR
2
GO
:0
00
80
16
Re
gu
la
tio
n 
of
 h
ea
rt 
co
nt
ra
ct
io
n
2E
-0
4
8
CA
M
K2
D,
 C
SR
P3
, G
ST
M
2,
 P
KP
2,
 P
LN
, R
YR
2,
 S
NT
A1
, T
M
EM
65
GO
:0
00
70
10
Cy
to
sk
el
et
on
 o
rg
an
is
at
io
n
3E
-0
4
16
AJ
UB
A,
 C
FL
2,
 C
SR
P3
, E
RB
B2
IP,
 F
HO
D3
, F
LI
I, 
LI
M
CH
1,
 M
YO
Z2
, N
TM
T1
, O
BS
CN
, 
PK
P2
, P
RK
CD
BP
, S
HA
NK
1,
 S
OR
BS
1,
 S
VI
L,
 T
UB
A4
A
GO
:0
05
51
19
Re
la
xa
tio
n 
of
 c
ar
di
ac
 m
us
cl
e
4E
-0
4
3
CA
M
K2
D,
 G
ST
M
2,
 P
LN
GO
:0
08
60
05
Ve
nt
ric
ul
ar
 c
ar
di
ac
 m
us
cl
e 
ce
ll 
ac
tio
n 
po
te
nt
ia
l
4E
-0
4
3
PK
P2
, R
YR
2,
 S
NT
A1
GO
:0
05
51
17
Re
gu
la
tio
n 
of
 c
ar
di
ac
 m
us
cl
e 
co
nt
ra
ct
io
n
4E
-0
4
5
CA
M
K2
D,
 G
ST
M
2,
 P
KP
2,
 P
LN
, R
YR
2
GO
:0
00
20
26
Re
gu
la
tio
n 
of
 th
e 
fo
rc
e 
of
 h
ea
rt 
co
nt
ra
ct
io
n
4E
-0
4
4
CA
M
K2
D,
 C
SR
P3
, P
LN
, R
YR
2
GO
:1
90
10
77
Re
gu
la
tio
n 
of
 re
la
xa
tio
n 
of
 m
us
cl
e
6E
-0
4
2
CA
M
K2
D,
 P
LN
GO
:1
90
18
97
Re
gu
la
tio
n 
of
 re
la
xa
tio
n 
of
 c
ar
di
ac
 m
us
cl
e
6E
-0
4
2
CA
M
K2
D,
 P
LN
GO
:0
00
20
27
Re
gu
la
tio
n 
of
 h
ea
rt 
ra
te
8E
-0
4
5
CA
M
K2
D,
 P
KP
2,
 P
LN
, R
YR
2,
 S
NT
A1
GO
:0
00
69
42
Re
gu
la
tio
n 
of
 s
tri
at
ed
 m
us
cl
e 
co
nt
ra
ct
io
n
1E
-0
3
5
CA
M
K2
D,
 G
ST
M
2,
 P
KP
2,
 P
LN
, R
YR
2
GO
:0
09
00
75
Re
la
xa
tio
n 
of
 m
us
cl
e
1E
-0
3
3
CA
M
K2
D,
 G
ST
M
2,
 P
LN
Ph
os
ph
or
yl
at
ed
GO
:0
03
10
32
Ac
to
m
yo
si
n 
st
ru
ct
ur
e 
or
ga
ni
sa
tio
n
1E
-0
5
5
CD
C4
2B
PB
, M
YL
K3
, M
YO
18
A,
 O
BS
CN
, S
OR
BS
1
GO
:0
05
07
89
Re
gu
la
tio
n 
of
 b
io
lo
gi
ca
l p
ro
ce
ss
3E
-0
4
25
AH
NA
K,
 B
AG
3,
 B
VE
S,
 C
DC
42
BP
B,
 J
PH
2,
 K
AN
K2
, K
PN
A4
, L
RR
FI
P2
, M
AP
T,
 
M
YL
K3
, M
YO
18
A,
 N
UC
KS
1,
 O
BS
CN
, O
SB
P, 
PL
CL
1,
 P
LN
, P
SI
P1
, R
BM
20
, R
SF
1,
 
SC
N7
A,
 S
GT
A,
 S
OR
BS
1,
 S
PE
G,
 S
TX
4,
 Z
BT
B7
A
GO
:0
05
08
48
Re
gu
la
tio
n 
of
 c
al
ci
um
-m
ed
ia
te
d 
si
gn
al
lin
g
4E
-0
4
3
JP
H2
, M
AP
T,
 P
LN
GO
:1
90
10
19
Re
gu
la
tio
n 
of
 c
al
ci
um
 io
n 
tra
ns
m
em
br
an
e 
tra
ns
po
rte
r a
ct
iv
ity
4E
-0
4
3
AH
NA
K,
 J
PH
2,
 P
LN
group.bmj.com on February 21, 2018 - Published by http://openheart.bmj.com/Downloaded from 
11Bond AR, et al. Open Heart 2018;5:e000716. doi:10.1136/openhrt-2017-000716
Table 6 List of proteins and associated gene name 
abbreviations
Gene symbol Protein name
ADCY6 Adenylate cyclase type 6
AHNAK Neuroblast differentiation-associated protein AHNAK
AJUBA LIM domain-containing protein ajuba
BAG3 BAG family molecular chaperone regulator 3
BCAT2
Branched-chain-amino-acid aminotransferase, 
mitochondrial
BCKDHA
2-Oxoisovalerate dehydrogenase subunit alpha, 
mitochondrial
BCKDK
(3-methyl-2-oxobutanoate dehydrogenase (lipoamide)) 
kinase, mitochondrial
BVES Blood vessel epicardial substance
C6orf57 Chromosome six open reading frame 57
CAMK2D
Calcium/calmodulin-dependent protein kinase type II subunit 
delta
CDC42BPB Serine/threonine-protein kinase MRCK beta
CDH2 Cadherin-2
CFL2 Cofilin-2
CMYA5 Cardiomyopathy-associated protein 5
COA5 Cytochrome c oxidase assembly factor 5
COBL Protein cordon-bleu
COL6A5 Collagen alpha-5(VI) chain
COX1 Cytochrome c oxidase subunit 1
CPT2 Carnitine O-palmitoyltransferase 2, mitochondrial
CSRP3 Cysteine and glycine-rich protein 3
DMD Dystrophin
ERBB2IP Protein LAP2
FDX1 Adrenodoxin, mitochondrial
FHOD3 FH1/FH2 domain-containing protein 3
FLII Protein flightless-1 homolog
FLNC Filamin-C
GSTM2 Glutathione S-transferase Mu 2
HNRNPD Heterogeneous nuclear ribonucleoprotein D0
HRC
Sarcoplasmic reticulum histidine-rich calcium-binding 
protein
JPH2 Junctophilin-2
KANK2 KN motif and ankyrin repeat domain-containing protein 2
KPNA4 Importin subunit alpha-3
KRT10 Keratin, type I cytoskeletal 10
KRT14 Keratin, type I cytoskeletal 14
LCN2 Neutrophil gelatinase-associated lipocalin
LDB3 LIM domain binding 3 isoform 1
LIMCH1 LIM and calponin homology domains-containing protein 1
LRRFIP2 Leucine-rich repeat flightless-interacting protein 2
MAPT Microtubule-associated protein
MRPL12 39S Ribosomal protein L12, mitochondrial
MYLK3 Myosin light chain kinase 3
MYO18A Unconventional myosin-XVIIIa
MYOM1 Myomesin-1
MYOM2 Myomesin (M-protein) 2, 165 kDa, isoform CRA_c
MYOZ2 Myozenin-2
ND1 NADH-ubiquinone oxidoreductase chain 1
NEBL Nebulette
NTMT1 N-terminal Xaa-Pro-Lys N-methyltransferase 1
NUCKS1 Nuclear ubiquitous casein and cyclin-dependent kinase 
substrate 1
Continued
Gene symbol Protein name
OBSCN Obscurin
OGDH 2-Oxoglutarate dehydrogenase, mitochondrial
OSBP Oxysterol-binding protein 1
PKP2 Plakophilin-2
PLCL1 Inactive phospholipase C-like protein 1
PLN Cardiac phospholamban
PPM1K Protein phosphatase 1K, mitochondrial
PPP3CC
Serine/threonine-protein phosphatase 2B catalytic subunit 
gamma isoform
PRKAR2A
Protein kinase cAMP-dependent regulatory type II alpha 
isoform 1
PRKCDBP Protein kinase C delta-binding protein
PSIP1 PC4 and SFRS1-interacting protein
RBM20 RNA-binding protein 20
RSF1 Remodelling and spacing factor 1
RYR2 Ryanodine receptor 2
SCN7A Sodium channel protein type 7 subunit alpha
SDHD
Succinate dehydrogenase (ubiquinone) cytochrome b small 
subunit, mitochondrial
SDHAF1 Succinate dehydrogenase assembly factor 1, mitochondrial
SEMA3C Semaphorin-3C
SGTA
Small glutamine-rich tetratricopeptide repeat-containing 
protein alpha (Alpha-SGT) (Vpu-binding protein) (UBP)
SHANK1 SH3 and multiple ankyrin repeat domains protein 1
SNTA1 Alpha-1-syntrophin
SNTB2 Beta-2-syntrophin
SORBS1 Sorbin and SH3 domain-containing protein 1
SPEG Striated muscle preferentially expressed protein kinase
SRL Sarcalumenin
STRN Striatin
STX4 Syntaxin-4
SVIL Supervillin
SYNPO2L Synaptopodin 2-like, isoform CRA_a
TIMM22
Mitochondrial import inner membrane translocase subunit 
Tim22
TMEM65 Transmembrane protein 65
TNNI3 Mutant cardiac troponin I
TPM1 Tropomyosin 1 (Alpha), isoform CRA_a
TSFM Elongation factor Ts, mitochondrial
TUBA4A Tubulin alpha-4A chain
TUBB4A Tubulin beta-4A chain
TWF2 Twinfilin-2
XIRP1 Xin actin-binding repeat-containing protein 1
ZBTB7A Zinc finger and BTB domain-containing protein 7A
Table 6 Continued 
Basic and translational research
other proteins surround and support these to make up 
the sarcomeric scaffold, which affects the efficiency and 
transmission of the generated force.6 In our patients, 
there were no significant differences in expression 
between actin or myosin; however in the RV of hearts 
with high after load, as in TOF, there were increases in 
the amounts of supporting proteins, for example, muscle 
LIM protein, filamin-C, obscurin, myomesin-1 and ZASP, 
which have roles in cross-linking and connecting fila-
ments, Z-disc assembly, mechano-sensing and myocyte 
signalling.7–13 The evidence that MYOM1 is present in the 
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Figure 3 Hierarchy of enriched gene ontology biological processes for expression of proteins that are higher in patients with 
TOF compared with VSD. Highlighted terms correspond to table 5. Figure exported from GOrilla analysis. TOF, tetralogy of 
Fallot; VSD, ventricular septal defect.
Table 7 Clinical outcome data
Group 1 
VSD n=6
Group 2 
TOF n=6 P value
Ventilation time (median days) 0.833 5.2 ns
SVC pressure (median mm Hg) 11.2 10.7 ns
Dopamine (median peak rate, 
µg/kg/min)
4.2 7.5 ns
Dopamine (median hours) 12.5 59 ns
Milrinone (median peak rate, µg/
kg/min)
0.5 0.57 ns
Milrinone (median hours) 39.7 88 ns
Pleural drains (median days) 2.3 2.3 ns
Arrhythmias (number of children) 2 3 ns
Oxygen duration (median, days) 2 5.1 0.043
Intensive care stay (median, 
days)
2.7 4.5 ns
Hospital stay (median days) 6.5 9.5 ns
SVC, superior vena cava; TOF, tetralogy of Fallot; VSD, ventricular 
septal defect.
myocardium of neonatal dogs might have relevance to 
our patients, if we later found it to be reduced in amount 
in older children with the same condition.12 It is possible 
that overexpression of these proteins is linked with 
decreased ability to relax and that there is failure of the 
RV to develop past the phenotype seen in the neonate. 
Further studies would be needed to determine whether 
this disappears in older children with TOF once repair 
had been performed. The giant protein titin stretches 
between the Z-disc and M-line of the sarcomere and is 
thought to be a key player in passive myocardial stiff-
ness and contraction.14 15 Our data showed a non-signifi-
cant increase (1.4-fold) in titin content of TOF samples; 
further interrogation showed no significant correlation 
between titin expression and E/A wave ratio as a stiffness 
indicator. However, previous work has shown that it may 
be the ratio of cardiac titin isoforms that is important 
in heart failure and stiffness (which was not looked at 
here) and not total expression.15 We have shown that 
in the hearts of infants with TOF, which have evidence 
of increased stiffness and pressure afterload, there is an 
increase in some of the contractile proteins. It should 
however be noted that in this study, due to unavail-
ability of healthy patient control tissue, we cannot defin-
itively say that proteins are abnormally altered in either 
pathology, only that there are differences between the 
pathologies. It is unclear whether the predominantly 
enhanced expression of proteins in TOF is due to right 
ventricular remodelling of the myocytes and the onset 
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Basic and translational research
of hypertrophy or a compensatory mechanism. Studies 
on aortas from rats with type 2 diabetes have shown that 
increased ROS caused by oxidative stress upregulates 
contractile protein expression resulting in vascular wall 
remodelling.16
Perhaps of greater importance is the differences in 
phosphorylation of proteins involved in the ventricle 
contractile processes. Phosphorylation of proteins indi-
cates a change in protein function (either activation 
or deactivation) and enrichment was seen in proteins 
at various phosphorylation sites with higher levels in 
TOF, associated with calcium signalling and contractility 
pathways. Of the phosphorylation sites we detected in 
our proteomics analysis, many of them have not been 
detected previously in heart tissue (PhosphositePlus, 
accessed March 201717), the exceptions being the 
following (R denotes regulatory protein, and K denotes 
associated kinases where known): phospholamban-ser16 
(R: protein phosphatase 1 regulatory inhibitor subunit 
1A,18 K: cAMP-dependent protein kinase catalytic subunit 
alpha19) and -thr17 (R: tumour necrosis factor-α receptor 
subtypes 1 and 2,20 K: cAMP-dependent protein kinase 
catalytic subunit alpha19), myomesin 2-ser76 (K: cAMP-de-
pendent protein kinase catalytic subunit alpha,21 protein 
kinase cAMP-dependent regulatory type II-α-ser78 and 
cardiac troponin I-ser199) (K: cAMP-dependent protein 
kinase catalytic subunit alpha).22 The interaction of 
cardiac troponin I-Ser199 with its putative kinase has 
been shown to be inhibited by tropomyosin I,23 which was 
significantly higher in TOF samples, resulting in altered 
force of contraction.
Previous studies have shown some changes in calcium 
signalling in congenital heart disease, but it has not been 
possible to determine whether this is a generic response 
to RV hypertension or to specific cardiac physiologies.24 
Proteins associated with calcium signalling were detected 
with adenylate cyclase 6, calcium/calmodulin-dependent 
protein kinase, phospholamban, ryanodine receptor 
2 and sarcalumenin all being significantly higher in 
TOF. Phosphosites for phospholamban at Ser16, sarco-
plasmic reticulum histidine-rich calcium-binding protein 
at Ser145 and junctophilin-2 at Thr490 were higher in 
TOF. However, cardiac troponin I at Ser199 was lower. 
The finding for phospholamban-Ser16 is similar to our 
previous studies and was linked to hypoxaemia.25 26
Although children with TOF clearly are more cyanosed, 
it is not clear how this would affect the RV. The biopsies 
are taken from the cavity of the RV that would normally 
see the venous (desaturated) blood. Systemic desatura-
tion would not be expected to affect the endocardial 
surface of the RV.27 28 It should be noted that hypoxia-in-
ducible factor-1-alpha (HIF-1α) was not detected in our 
proteomics analysis, despite oxygen saturation levels indi-
cating hypoxia, especially in the TOF patients. It would 
be expected that HIF-1α be present in all our samples 
as has previously been described for CHD,29 suggesting 
the abundance was too low to detect with our protocol. 
However, we know that the RV is stiff after definitive 
cardiac surgery for TOF, which might relate to abnormal-
ities of contractile proteins, secondary to an obstructed 
RV in comparison with the volume loaded RV of children 
with large post-tricuspid left to right shunt (VSD).30 For 
the first time, we have made a direct comparison between 
the hypertensive RV of children with VSD and the RV of 
children with TOF.
The novel findings for the rest of the proteins/
phosphoproteins provide further evidence for maladapta-
tion of the RV in cyanotic TOF patients with implications 
for increased stiffness after open-heart surgery. The lack 
of functional measurements, for instance, single permea-
bilised cardiomyocyte measurements to assess systolic and 
diastolic properties, calcium sensitivity and cross-bridge 
kinetics, make it difficult to understand the functional 
relevance of the observed differences in cellular signal-
ling between the two patient groups. It would be helpful 
to understand this in future studies, but the amount of 
tissue available from such small children limits the possi-
bility under the current approvals for this study. A large 
piece of RV tissue would be required, and there is some 
doubt that the digestion process required to achieve 
single cells might render the sample unrepresentative.
Comparison with known cardiac disease
Genes known to be affected in myocardial disorders with 
ventricular dysfunction (hypertrophic cardiomyopathy 
(HCM), dilated cardiomyopathy (DCM) and arrhythmo-
genic right ventricular cardiomyopathy (ARVC) (KEGG 
(Kyoto Encyclopaedia of Genes and Genomes) pathways 
map0510, map0514 and map05412 respectively31) were 
compared with our proteomics data. The majority of 
the affected proteins in these diseases were also present 
in our samples (11/15 HCM, 9/13 DCM, 5/6 ARVC); 
however, only tropomyosin-1 (normally affected in HCM 
and DCM, but not ARVC) was significantly higher in 
TOF samples. This suggests there was no downregula-
tion of contractility as seen in maladaptation and right 
ventricular cardiomyopathy but more likely the upregula-
tion due to increased myocardial wall stress.32
ConCluSion
For the first time, it is now possible to suggest a cellular 
mechanism for the stiff RV in TOF, in that we have shown 
abnormalities in the calcium signalling pathways of the 
right ventricular myocardium. We have shown increased 
expression of myocardial contractile and extracellular 
proteins in TOF as compared with VSD, showing an adap-
tive physiology that is unrelated to age. We have shown 
that there is also parallel abnormality of clinical, echo-
cardiographic and outcome data that might allow us, 
in future, to customise the treatment of the individual 
child in relation to their post-translational proteomics. 
It is too early to relate one finding directly to the other, 
but further work needs to be performed to determine 
the relationship between these important changes in RV 
hypertension in congenital heart disease.
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